Partnership formed for vision restoration

Article

The Max Planck Society (Max-Planck-Gesellschaft) and Fovea Pharmaceuticals (the ophthalmology division of Sanofi) have announced the formation of a partnership to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

The Max Planck Society (Max-Planck-Gesellschaft) and Fovea Pharmaceuticals (the ophthalmology division of Sanofi) have announced the formation of a partnership to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

This research collaboration and licence agreement will last for 3 years and will see the Fovea team work with the Max Planck Institute of Biophysics, led by Professor Ernst Bamberg, who pioneered the understanding of the application of retinal binding channelrhodopsins and was one of the founders of optogenetics. Professor Bamberg commented, "The cooperation is a big step forward to bring the optogenetic approach to the clinics."

The agreement will complement other collaborations of Fovea and will further advance research on the retinal binding protein channelrhodopsin 2 (ChR2) and its application in retinal diseases. It is hoped that a successful outcome of this research will result in restoration of visual function in patients suffering from reduced vision or blindness.

Under the terms of the agreement the Max Planck Institute will receive a total of €450,000 and Sanofi will be given priority access to the technology, inventions and derived technologies of the Max Planck Institute research activities in ChR2.

For more information visit the Max Planck Society's website at www.mpg.de

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.